专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US09139880B2 Identification of tumor-associated cell surface antigens for diagnosis and therapy 有权
标题翻译：鉴定肿瘤相关细胞表面抗原进行诊断和治疗
公开(公告)号：US09139880B2
公开(公告)日：2015-09-22
申请号：US13863780
申请日：2013-04-16
申请人： BioNTech AG
发明人： Özlem Türeci , Ugur Sahin , Gerd Helftenbein , Volker Schlüter
IPC分类号： C12Q1/68 , C07K14/47 , C07K14/705 , C07K16/30 , G01N33/574 , A61K39/00
CPC分类号： G01N33/57492 , A61K2039/505 , C07K14/4748 , C07K14/705 , C07K16/30 , C07K2317/34 , C12Q1/6886 , C12Q2600/112 , C12Q2600/158 , G01N2800/56
摘要： The present invention provides agents with tumor-inhibiting activity, and which are selective for cells expressing or abnormally expressing a tumor-associated antigen. Said tumor-associated antigen has a nucleotide sequence selected from the group consisting of: (a) a nucleotide sequence selected from the specific sequences set forth herein, or a 6-50 contiguous nucleotide residue portion thereof; (b) a nucleotide sequence of a nucleic acid which hybridizes with a nucleic acid having the nucleotide sequence of (a) under stringent conditions; (c) a nucleotide sequence which is degenerate with respect to the nucleotide sequence of (a) or (b); and (d) a nucleotide sequence which is complementary to the nucleotide sequence of (a), (b) or (c). Pharmaceutical compositions and kits comprising the agents are also provided, as well as methods treating, diagnosing or monitoring a disease characterized by expression or abnormal expression of the tumor-associated antigen.
摘要翻译：本发明提供具有肿瘤抑制活性的药剂，并且其对表达或异常表达肿瘤相关抗原的细胞是选择性的。所述肿瘤相关抗原具有选自以下的核苷酸序列：（a）选自本文所述的特定序列的核苷酸序列或其6-50个连续核苷酸残基部分; （b）在严格条件下与具有（a）的核苷酸序列的核酸杂交的核酸的核苷酸序列; （c）相对于（a）或（b）的核苷酸序列退化的核苷酸序列; 和（d）与（a），（b）或（c）的核苷酸序列互补的核苷酸序列。还提供了包含这些试剂的药物组合物和试剂盒，以及治疗，诊断或监测以肿瘤相关抗原的表达或异常表达为特征的疾病的方法。

2. 发明授权

US09267177B2 Identification of tumor-associated cell surface antigens for diagnosis and therapy 有权
公开(公告)号：US09267177B2
公开(公告)日：2016-02-23
申请号：US14830506
申请日：2015-08-19
申请人： BioNTech AG
发明人： Özlem Türeci , Ugur Sahin , Gerd Helftenbein , Volker Schlüter
IPC分类号： C12Q1/68
CPC分类号： G01N33/57492 , A61K2039/505 , C07K14/4748 , C07K14/705 , C07K16/30 , C07K2317/34 , C12Q1/6886 , C12Q2600/112 , C12Q2600/158 , G01N2800/56
摘要： The present invention provides agents with tumor-inhibiting activity, and which are selective for cells expressing or abnormally expressing a tumor-associated antigen. Said tumor-associated antigen has a nucleotide sequence selected from the group consisting of: (a) a nucleotide sequence selected from the specific sequences set forth herein, or a 6-50 contiguous nucleotide residue portion thereof; (b) a nucleotide sequence of a nucleic acid which hybridizes with a nucleic acid having the nucleotide sequence of (a) under stringent conditions; (c) a nucleotide sequence which is degenerate with respect to the nucleotide sequence of (a) or (b); and (d) a nucleotide sequence which is complementary to the nucleotide sequence of (a), (b) or (c). Pharmaceutical compositions and kits comprising the agents are also provided, as well as methods treating, diagnosing or monitoring a disease characterized by expression or abnormal expression of the tumor-associated antigen.

3. 发明授权

US09910043B2 Identification of tumor-associated cell surface antigens for diagnosis and therapy 有权
公开(公告)号：US09910043B2
公开(公告)日：2018-03-06
申请号：US15046700
申请日：2016-02-18
申请人： BioNTech AG
发明人： Özlem Türeci , Ugur Sahin , Gerd Helftenbein , Volker Schlüter
IPC分类号： G01N33/574 , C07K14/47 , C07K14/705 , C07K16/30 , C12Q1/68 , A61K39/00
CPC分类号： G01N33/57492 , A61K2039/505 , C07K14/4748 , C07K14/705 , C07K16/30 , C07K2317/34 , C12Q1/6886 , C12Q2600/112 , C12Q2600/158 , G01N2800/56
摘要： The present invention provides agents with tumor-inhibiting activity, and which are selective for cells expressing or abnormally expressing a tumor-associated antigen. Said tumor-associated antigen has a nucleotide sequence selected from the group consisting of: (a) a nucleotide sequence selected from the specific sequences set forth herein, or a 6-50 contiguous nucleotide residue portion thereof; (b) a nucleotide sequence of a nucleic acid which hybridizes with a nucleic acid having the nucleotide sequence of (a) under stringent conditions; (c) a nucleotide sequence which is degenerate with respect to the nucleotide sequence of (a) or (b); and (d) a nucleotide sequence which is complementary to the nucleotide sequence of (a), (b) or (c). Pharmaceutical compositions and kits comprising the agents are also provided, as well as methods treating, diagnosing or monitoring a disease characterized by expression or abnormal expression of the tumor-associated antigen.

4. 发明授权

US09533043B2 Identification of surface-associated antigens for tumor diagnosis and therapy 有权
标题翻译：鉴定肿瘤诊断和治疗的表面相关抗原
公开(公告)号：US09533043B2
公开(公告)日：2017-01-03
申请号：US14036969
申请日：2013-09-25
申请人： BioNTech AG
发明人： Özlem Türeci , Ugur Sahin , Sandra Schneider , Gerd Helftenbein , Volker Schlüter , Dirk Usener , Philippe Thiel , Michael Koslowski
IPC分类号： A61K39/395 , A61K51/10 , A61K47/42 , C07K16/30 , C12Q1/68 , C07K14/47 , A61K45/06 , C07K16/28 , A61P35/00 , G01N33/53
CPC分类号： A61K39/39558 , A61K39/395 , A61K45/06 , C07K14/4748 , C07K16/28 , C07K16/30 , C12Q1/6886 , C12Q2600/106 , C12Q2600/156 , G01N33/53
摘要： An isolated truncated desmoglein 4 (DSG4) polypeptide splice variant of the invention is characterized by an amino acid sequence that lacks a region encoded before exon 9 or beyond exon 10 of the DSG4 gene having the polynucleotide sequence of SEQ ID NO: 75. Also disclosed is a method of diagnosing a cancer, or monitoring the course thereof, in a patient. The method comprises detecting in a tissue sample of a patient the expression of a tumor-associated antigen comprising the extracellular domain of a DSG4 polypeptide encoded by a DSG4 gene having the polynucleotide sequence of SEQ ID NO: 75, or a truncated DSG4 polypeptide splice variant characterized by an amino acid sequence that lacks a region encoded before exon 9 or beyond exon 10 of the DSG4 gene.
摘要翻译：本发明的分离的截短的脱骨髓蛋白4（DSG4）多肽剪接变体的特征在于缺乏在具有SEQ ID NO：75的多核苷酸序列的DSG4基因的外显子9或超出外显子10之前编码的区域的氨基酸序列。还公开了是在患者中诊断癌症或监测其过程的方法。该方法包括在患者的组织样品中检测包含由具有SEQ ID NO：75的多核苷酸序列的DSG4基因或截短的DSG4多肽剪接变体编码的DSG4多肽的细胞外结构域的肿瘤相关抗原的表达其特征在于缺乏在DSG4基因的外显子9或超出外显子10之前编码的区域的氨基酸序列。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式